20.53
BATS BZX Real-Time Price
As of 3:30pm ET
 +1.06 / +5.44%
Today’s Change
11.25
Today|||52-Week Range
22.59
+32.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$973.4M

Company Description

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Its main product ARIKAYCE or LAI, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. Insmed was founded on November 29, 1999 and is headquartered in Monmouth Junction, NJ.

Contact Information

Insmed, Inc.
9 Deer Park Drive
Monmouth Junction New Jersey 08852-1923
P:(732) 997-4600
Investor Relations:

Employees

Shareholders

Individual stakeholders6.29%
Other institutional46.63%
Mutual fund holders40.82%

Top Executives

William H. LewisPresident, Chief Executive Officer & Director
Andrew T. DrechslerChief Financial Officer
Walter R. PerkinsChief Technology Officer
Peter M. ClarkeVice President-Technical Operations
John GollVice President & Corporate Controller

To view my watchlist

Not a member yet?

Sign up now for a free account